Description
TG101348 is an inhibitor of JAK2 that is currently in clinical trials as a potential treatment for myelofibrosis. TG101348 exhibits immunomodulatory and anticancer chemotherapeutic activities. In cells acquired from acute coronary syndrome patients, TG101348 decreases expression of Th17 cells and increases expression of Treg cells. TG101348 inhibits cellular proliferation of Hodgkin lymphoma cells and mediastinal large B-cell lymphoma cells; in vivo, this compound decreases tumor growth and increases survival. In animal models of myeloproliferative disease, TG101348 decreases hematocrit and leukocyte count, somewhat attenuating myelofibrosis.